Crossmark

Cardiovascular toxicities associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a pharmacovigilance study based on FDA adverse event reporting system

Crossref DOI link: https://doi.org/10.1007/s11096-025-01962-8

Published Online: 2025-07-02

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Yao

Deng, Junge

Wang, Jize https://orcid.org/0009-0007-9194-7978
Funding

Funding for this research was provided by:

Natural Science Foundation of Gansu Province (No. 24JRRA347.)

National Natural Science Foundation of China (82203267)

Cuiying Scientific and Technological Innovation Program of Lanzhou Unversity Second Hospital (CY2022-MS-A12)
License Information

Text and Data Mining valid from 2025-07-02

Version of Record valid from 2025-07-02
More Information

Article History

Received: 24 February 2025

Accepted: 28 May 2025

First Online: 2 July 2025

Conflicts of interest

: The authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below